SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Dated July 23, 2020
Commission File Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
(Translation of Registrants Name)
#1203-4464 Markham Street
Victoria, British Columbia
(Address and telephone number of registrants principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☒ No ☐
This Form 6-K is hereby filed and incorporated by reference in the registrants Registration Statement on Form F-10 (File No. 333-238785).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: July 23, 2020
|Aurinia Pharmaceuticals Inc.|
|Name: Peter S. Greenleaf|
|Title: Chief Executive Officer|
Description of Exhibit
|99.1||Material Change Report, dated July 23, 2020 U.S. Food and Drug Administration acceptance of New Drug Application|
|99.2||Material Change Report, dated July 23, 2020 Underwritten Public Offering|
|99.3||Underwriting Agreement, dated July 22, 2020|
|99.4||News Release Aurinia Prices US$200 Million Public Offering of Common Shares|
Exhibit 99.1, 99.2, 99.3 and 99.4 included with this report on Form 6-K are hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-238785), as amended or supplemented.